Alliance Global Partners Downgrades Aptose Biosciences (TSE:APS) to Hold

Aptose Biosciences (TSE:APS) (NASDAQ:APTO) was downgraded by analysts at Alliance Global Partners from a “strong-buy” rating to a “hold” rating in a report released on Monday,Zacks.com reports.

Aptose Biosciences Trading Up 0.9%

Shares of TSE APS opened at C$2.31 on Monday. The firm’s 50 day moving average price is C$1.83 and its 200-day moving average price is C$1.88. Aptose Biosciences has a 52-week low of C$1.02 and a 52-week high of C$16.50. The company has a debt-to-equity ratio of -117.37, a quick ratio of 5.41 and a current ratio of 1.05. The company has a market cap of C$5.90 million, a PE ratio of 3.35 and a beta of -0.05.

Aptose Biosciences (TSE:APS) (NASDAQ:APTO) last announced its quarterly earnings results on Thursday, November 13th. The biotechnology company reported C($2.01) earnings per share for the quarter. On average, equities research analysts expect that Aptose Biosciences will post -0.59 EPS for the current fiscal year.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.